Edition:
United States

Navidea Biopharmaceuticals Inc (NAVB.A)

NAVB.A on American Stock Exchange

0.41USD
18 Aug 2017
Change (% chg)

$-0.00 (-0.20%)
Prev Close
$0.41
Open
$0.40
Day's High
$0.41
Day's Low
$0.40
Volume
10,823
Avg. Vol
39,063
52-wk High
$1.14
52-wk Low
$0.26

Latest Key Developments (Source: Significant Developments)

Navidea Biopharmaceuticals reports Q2 loss per share $0.03
Tuesday, 8 Aug 2017 09:05pm EDT 

Aug 9 (Reuters) - Navidea Biopharmaceuticals Inc -:Navidea Biopharmaceuticals reports second quarter 2017 financial results.Q2 revenue $612,000 versus $1.2 million.Q2 loss per share $0.03.  Full Article

Navidea enters exclusive license, distribution agreement for India with Sayre Therapeutics
Tuesday, 20 Jun 2017 10:37am EDT 

June 20 (Reuters) - Navidea Biopharmaceuticals Inc ::Navidea enters exclusive license and distribution agreement for India with Sayre Therapeutics.Agreement with Sayre Therapeutics for development and commercialization of tc 99m tilmanocept in india.Under terms, Co eligible to receive milestone payments, royalties associated with sale of tc 99m Tilmanocept in India.Under terms of agreement, Navidea received an upfront payment.  Full Article

Navidea says commercial partner Norgine launches lymphoseek in Europe
Monday, 12 Jun 2017 11:06am EDT 

June 12 (Reuters) - Navidea Biopharmaceuticals Inc ::Navidea’s commercial partner, Norgine B.V., launches lymphoseek in Europe.European commercial partner, SpePharm AG, launched lymphoseek in Denmark, Netherlands and UK.  Full Article

Navidea Biopharmaceuticals says on May 12, co got a ruling in favor of Ricardo Gonzalez finding that he was terminated by co without cause - SEC Filing
Tuesday, 16 May 2017 04:56pm EDT 

May 16 (Reuters) - Navidea Biopharmaceuticals Inc :Navidea Biopharmaceuticals - On May 12, co got a ruling in favor of Ricardo J. Gonzalez finding that he was terminated by co without cause - SEC Filing.Navidea - Gonzalez was awarded severance, bonus and benefits of $517,978 plus statutory interest from April 7, 2016, attorneys' fees.  Full Article

Navidea Biopharmaceuticals reports Q1 earnings $0.53/shr
Tuesday, 9 May 2017 04:15pm EDT 

May 9 (Reuters) - Navidea Biopharmaceuticals Inc :Navidea Biopharmaceuticals reports first quarter 2017 financial results.Q1 revenue $580,000 versus $948,000.Q1 earnings per share $0.53.  Full Article

Navidea Q4 loss per share $0.02
Wednesday, 29 Mar 2017 04:05pm EDT 

Navidea Biopharmaceuticals Inc : Navidea provides corporate update and reports full year 2016 results . Q4 loss per share $0.02 .Q4 revenue $3.4 million versus $4.3 million.  Full Article

Cardinal Health reports 5.8 pct passive stake in Navidea Biopharma
Monday, 13 Mar 2017 04:03pm EDT 

Cardinal Health Inc :Cardinal Health, Inc reports 5.8 percent passive stake in navidea biopharmaceuticals inc as of March 3, 2017 - sec filing.  Full Article

Navidea Biopharmaceuticals says reaches settlement with CRG relating to loan agreement
Thursday, 23 Feb 2017 10:32am EST 

Navidea Biopharmaceuticals Inc : Navidea Biopharmaceuticals - On Feb 22, 2017, Co, CRG, and Cardinal Health 414 read into record a settlement in interpleader action pending in Ohio . Navidea Biopharmaceuticals Inc - Parties agreed that CRG will be paid $59 million - SEC filing . Navidea Biopharmaceuticals - Co, CRG agreed that the $2 million currently being held in escrow pursuant to court order in the Ohio case - SEC filing . Navidea Biopharmaceuticals Inc - Cardinal Health 414 will post a $7 million letter of credit in favor of CRG .Navidea Biopharmaceuticals - Co, CRG agreed $3 million currently being held in escrow pursuant to court order in Texas case to be released to co at closing of deal.  Full Article

Navidea enters into letter of intent with cardinal health for sale of Lymphoseek in North America
Tuesday, 6 Sep 2016 06:59am EDT 

Navidea Biopharmaceuticals Inc: Navidea Biopharmaceuticals enters into letter of intent with cardinal health for the sale of Lymphoseek® in North America . Total consideration to Navidea would be capped at $310 million. . Navidea retains rights to non-competitive diagnostic indications and all therapeutic applications .Navidea would receive $80 million at closing, with future consideration tied to annual sales of Lymphoseek, certain milestones.  Full Article

Navidea Biopharmaceuticals says files for non-timely 10-Q
Wednesday, 10 Aug 2016 03:46pm EDT 

Navidea Biopharmaceuticals Inc : Says files for non-timely 10-Q - SEC Filing . Says company is still in the process of gathering certain required documentation Source - http://bit.ly/2aMWOmN Further company coverage: [NAVB.A] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article